Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthhcare consulting, products, and services. The company has a strategic alliance with Carna Health for the development of AI-powered CKD screening, early detection and CKD management for underserved populations. The company was incorporated in 2017 and is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Metrics to compare | SHL1y | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSHL1yPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | 21.8x | −0.6x | |
PEG Ratio | 1.73 | −0.06 | 0.00 | |
Price/Book | 0.0x | 2.2x | 2.6x | |
Price / LTM Sales | 0.0x | 2.4x | 3.3x | |
Upside (Analyst Target) | - | 92.9% | 38.1% | |
Fair Value Upside | Unlock | 20.5% | 4.5% | Unlock |